董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Chau Q. Khuong | 男 | Director | 44 | 未披露 | 未持股 | 2020-06-22 |
| Johan Christenson | 男 | Director | 62 | 未披露 | 未持股 | 2020-06-22 |
| Pablo Cagnoni | 男 | Director | 57 | 19.33万美元 | 未持股 | 2020-06-22 |
| John Valliant | 男 | President, Chief Executive Officer and Director | 50 | 139.96万美元 | 未持股 | 2020-06-22 |
| Damian Lamb | 男 | Director and Chairman of the Board of Director | 51 | 未披露 | 未持股 | 2020-06-22 |
| Pablo Cagnoni | -- | Director | 57 | 未披露 | 未持股 | 2020-06-22 |
| Pablo Cagnoni | 男 | Director | 57 | 未披露 | 未持股 | 2020-06-22 |
| Steve Gannon | 男 | Director | 58 | 未披露 | 未持股 | 2020-06-22 |
| Heather Preston | 女 | Director | 54 | 未披露 | 未持股 | 2020-06-22 |
| Elisha P. Gould III | 男 | Director | 63 | 未披露 | 未持股 | 2020-06-22 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John Crowley | 男 | Chief Financial Officer | 47 | 84.99万美元 | 未持股 | 2020-06-22 |
| John Valliant | 男 | President, Chief Executive Officer and Director | 50 | 139.96万美元 | 未持股 | 2020-06-22 |
| Eric Burak | -- | Chief Scientific Officer | 55 | 48.37万美元 | 未持股 | 2020-06-22 |
| James O'Leary | 男 | Chief Medical Officer | 55 | 未披露 | 未持股 | 2020-06-22 |
董事简历
中英对照 | 中文 | 英文- Chau Q. Khuong
-
Chau Q. Khuong，2013年8月以来，他一直在我们的董事会任职。目前他在OrbiMed Advisers LLC（风险投资和资产管理公司，他在2003年加入）的私人股本合伙人。他目前在Cerapedics, Inc., Aerpio Therapeutics, Inc., Inspire Medical Systems, Inc.和 Pieris AG。 的董事会任职。他获得Yale University的分子生物学学士学位（生物技术方向）公共卫生硕士学位（传染病学）。
Chau Q. Khuong has served as a member of our board of directors since 2020. Mr. Khuong is currently a Private Equity Partner at OrbiMed Advisors LLC, an investment firm. Mr. Khuong currently serves as a director of several publicly traded companies, including Fusion Pharmaceuticals Inc., a pharmaceutical company, since March 2019 Inspire Medical Systems, Inc. since May 2014 NextCure, Inc., a biopharmaceutical company, since December 2015 and Synlogic, Inc., a biotechnology company, since February 2016 as well as several private companies. Mr. Khuong holds a B.S. in molecular, cellular and development biology and an M.P.H. with a concentration in infectious diseases, both from Yale University. - Chau Q. Khuong，2013年8月以来，他一直在我们的董事会任职。目前他在OrbiMed Advisers LLC（风险投资和资产管理公司，他在2003年加入）的私人股本合伙人。他目前在Cerapedics, Inc., Aerpio Therapeutics, Inc., Inspire Medical Systems, Inc.和 Pieris AG。 的董事会任职。他获得Yale University的分子生物学学士学位（生物技术方向）公共卫生硕士学位（传染病学）。
- Chau Q. Khuong has served as a member of our board of directors since 2020. Mr. Khuong is currently a Private Equity Partner at OrbiMed Advisors LLC, an investment firm. Mr. Khuong currently serves as a director of several publicly traded companies, including Fusion Pharmaceuticals Inc., a pharmaceutical company, since March 2019 Inspire Medical Systems, Inc. since May 2014 NextCure, Inc., a biopharmaceutical company, since December 2015 and Synlogic, Inc., a biotechnology company, since February 2016 as well as several private companies. Mr. Khuong holds a B.S. in molecular, cellular and development biology and an M.P.H. with a concentration in infectious diseases, both from Yale University.
- Johan Christenson
-
Johan Christenson，2009年7月起，担任本公司董事。2001年至今，他一直是HealthCap的合伙人，这是一个风投基金，专注于全球范围内的制药、生物技术、医疗技术公司；目前是一些私营企业的董事。他在Karolinska Institute获得医学教育，于1991获得基础神经学博士学位。由于在早期阶段的医疗保健相关公司的丰富投资经验，他当选为本公司董事。
Johan Christenson has served as a member of our board of directors since February 2017. Dr. Christenson is a Partner of HealthCap Advisor AB. Prior to joining HealthCap Advisor AB in 2001 Dr. Christenson was with SEB Företagsinvest the venture capital arm of SEB to supervise its healthcare portfolio. He has senior management experience from Astra Pain Control as Project Director and AstraZeneca as Global Product Director and member of the global therapy area management team of pain and inflammation. Dr. Christenson serves as a member of the directors of Aprea Therapeutics, Inc., a clinical-stage oncology company. Dr. Christenson received his medical training at the Karolinska Institute and received his PhD in Neuroscience in 1991. He served as a lecturer in Neuroscience and also held a position as Assistant Dean at the Karolinska Institute Graduate School for two years. Dr. Christenson has four years of clinical specialist training in pediatrics and pediatric neurology. - Johan Christenson，2009年7月起，担任本公司董事。2001年至今，他一直是HealthCap的合伙人，这是一个风投基金，专注于全球范围内的制药、生物技术、医疗技术公司；目前是一些私营企业的董事。他在Karolinska Institute获得医学教育，于1991获得基础神经学博士学位。由于在早期阶段的医疗保健相关公司的丰富投资经验，他当选为本公司董事。
- Johan Christenson has served as a member of our board of directors since February 2017. Dr. Christenson is a Partner of HealthCap Advisor AB. Prior to joining HealthCap Advisor AB in 2001 Dr. Christenson was with SEB Företagsinvest the venture capital arm of SEB to supervise its healthcare portfolio. He has senior management experience from Astra Pain Control as Project Director and AstraZeneca as Global Product Director and member of the global therapy area management team of pain and inflammation. Dr. Christenson serves as a member of the directors of Aprea Therapeutics, Inc., a clinical-stage oncology company. Dr. Christenson received his medical training at the Karolinska Institute and received his PhD in Neuroscience in 1991. He served as a lecturer in Neuroscience and also held a position as Assistant Dean at the Karolinska Institute Graduate School for two years. Dr. Christenson has four years of clinical specialist training in pediatrics and pediatric neurology.
- Pablo Cagnoni
-
Pablo Cagnoni，2015年12月起，担任本公司的董事；自2015年5月起，担任 MPM Capital, Inc的董事总经理。另外，他还从2015年5月起，担任生物技术公司Tizona Pharmaceuticals, Inc.的总裁、首席执行官。此前，2013年10月至2015年4月，他担任Onyx Pharmaceuticals, Inc的总裁；2013年4月至2013年10月，担任全球研发与技术运营执行副总裁。他还在下列生物技术公司担任过管理职务：Novartis AG的高级副总裁、临床开发全球总监，2009年10月至2013年4月；Allos Therapeutics, Inc.的高级副总裁、首席医学官，2007年3月至2009年9月；OSI Pharmaceuticals, Inc. 的首席医学官、临床研究与临床事务副总裁，2004年7月至2007年3月。他还曾在 University of Colorado担任医学副教授、骨骼移植项目实验室的助理主任。他在University of Buenos Aires School of Medicine获得了医学博士学位，在Mount Sinai Medical Center的血液和肿瘤专业，以及University of Colorado Health Sciences Center的干细胞专业从事过博士后工作。
Pablo Cagnoni has served on our Board of Directors since December 2015. Dr. Cagnoni has also served as Managing Director of MPM Capital, Inc., since May 2015. In addition, Dr. Cagnoni has served as President and Chief Executive Officer of Tizona Pharmaceuticals, Inc., a biotechnology company, since May 2015. Dr. Cagnoni previously served as President of Onyx Pharmaceuticals, Inc. from October 2013 to April 2015 and as Executive Vice President, Global Research and Development and Technical Operations from April 2013 to October 2013. Dr. Cagnoni also served in management roles at the following biotechnology companies: Senior Vice President and Global Head of Clinical Development at Novartis AG from October 2009 to April 2013 Senior Vice President and Chief Medical Officer at Allos Therapeutics, Inc. from March 2007 to September 2009 and Chief Medical Officer and Vice President of Clinical Research and Medical Affairs at OSI Pharmaceuticals, Inc. from July 2004 to March 2007. Dr. Cagnoni was also Assistant Professor of Medicine and Assistant Director Pharmacology Laboratory at the University of Colorado Bone Marrow Transplant Program. Dr. Cagnoni received an M.D. from the University of Buenos Aires School of Medicine. He continued with post-doctoral work in Hematology and Oncology at the Mount Sinai Medical Center and in Stem Cell Transplantation at the University of Colorado Health Sciences Center. - Pablo Cagnoni，2015年12月起，担任本公司的董事；自2015年5月起，担任 MPM Capital, Inc的董事总经理。另外，他还从2015年5月起，担任生物技术公司Tizona Pharmaceuticals, Inc.的总裁、首席执行官。此前，2013年10月至2015年4月，他担任Onyx Pharmaceuticals, Inc的总裁；2013年4月至2013年10月，担任全球研发与技术运营执行副总裁。他还在下列生物技术公司担任过管理职务：Novartis AG的高级副总裁、临床开发全球总监，2009年10月至2013年4月；Allos Therapeutics, Inc.的高级副总裁、首席医学官，2007年3月至2009年9月；OSI Pharmaceuticals, Inc. 的首席医学官、临床研究与临床事务副总裁，2004年7月至2007年3月。他还曾在 University of Colorado担任医学副教授、骨骼移植项目实验室的助理主任。他在University of Buenos Aires School of Medicine获得了医学博士学位，在Mount Sinai Medical Center的血液和肿瘤专业，以及University of Colorado Health Sciences Center的干细胞专业从事过博士后工作。
- Pablo Cagnoni has served on our Board of Directors since December 2015. Dr. Cagnoni has also served as Managing Director of MPM Capital, Inc., since May 2015. In addition, Dr. Cagnoni has served as President and Chief Executive Officer of Tizona Pharmaceuticals, Inc., a biotechnology company, since May 2015. Dr. Cagnoni previously served as President of Onyx Pharmaceuticals, Inc. from October 2013 to April 2015 and as Executive Vice President, Global Research and Development and Technical Operations from April 2013 to October 2013. Dr. Cagnoni also served in management roles at the following biotechnology companies: Senior Vice President and Global Head of Clinical Development at Novartis AG from October 2009 to April 2013 Senior Vice President and Chief Medical Officer at Allos Therapeutics, Inc. from March 2007 to September 2009 and Chief Medical Officer and Vice President of Clinical Research and Medical Affairs at OSI Pharmaceuticals, Inc. from July 2004 to March 2007. Dr. Cagnoni was also Assistant Professor of Medicine and Assistant Director Pharmacology Laboratory at the University of Colorado Bone Marrow Transplant Program. Dr. Cagnoni received an M.D. from the University of Buenos Aires School of Medicine. He continued with post-doctoral work in Hematology and Oncology at the Mount Sinai Medical Center and in Stem Cell Transplantation at the University of Colorado Health Sciences Center.
- John Valliant
-
John Valliant是我们的创始人，自2014年12月起担任首席执行官和董事会成员。从2008年3月到2018年10月，Valliant博士担任Probe开发和商业化中心（CPDC）的首席执行官，这是一家放射性药物研究与开发中心，他也创立了该中心。Valliant博士从1999年开始还担任麦克马斯特大学（McMaster University）化学与化学生物系的教授。Valliant博士在麦克马斯特大学（McMaster University）完成博士学位，还在哈佛医学院（Harvard Medical School）的阿伦·琼斯（Alun G.Jones）教授和麻省理工学院（Massachusetts Institute of Technology）的艾伦·戴维森（Alan Davison）教授的共同监督下完成博士后奖学金。
John Valliant is our founder and has served as Chief Executive Officer and as a member of our board of directors since December 2014. From March 2008 to October 2018 Dr. Valliant was the Chief Executive Officer at the Centre for Probe Development and Commercialization, or CPDC, a radiopharmaceutical research and development center, which he also founded. Since 1999 Dr. Valliant has also served as a Professor in the Department of Chemistry and Chemical Biology at McMaster University. Dr. Valliant completed his PhD at McMaster University, and also completed a post-doctoral fellowship under the joint supervision of professors Alun G. Jones of Harvard Medical School and Alan Davison of the Massachusetts Institute of Technology. - John Valliant是我们的创始人，自2014年12月起担任首席执行官和董事会成员。从2008年3月到2018年10月，Valliant博士担任Probe开发和商业化中心（CPDC）的首席执行官，这是一家放射性药物研究与开发中心，他也创立了该中心。Valliant博士从1999年开始还担任麦克马斯特大学（McMaster University）化学与化学生物系的教授。Valliant博士在麦克马斯特大学（McMaster University）完成博士学位，还在哈佛医学院（Harvard Medical School）的阿伦·琼斯（Alun G.Jones）教授和麻省理工学院（Massachusetts Institute of Technology）的艾伦·戴维森（Alan Davison）教授的共同监督下完成博士后奖学金。
- John Valliant is our founder and has served as Chief Executive Officer and as a member of our board of directors since December 2014. From March 2008 to October 2018 Dr. Valliant was the Chief Executive Officer at the Centre for Probe Development and Commercialization, or CPDC, a radiopharmaceutical research and development center, which he also founded. Since 1999 Dr. Valliant has also served as a Professor in the Department of Chemistry and Chemical Biology at McMaster University. Dr. Valliant completed his PhD at McMaster University, and also completed a post-doctoral fellowship under the joint supervision of professors Alun G. Jones of Harvard Medical School and Alan Davison of the Massachusetts Institute of Technology.
- Damian Lamb
-
Damian Lamb自2017年2月以来一直担任我们的董事长兼董事会成员。Lamb自2000年起担任Genesys Capital Management Inc.（一家风险投资公司）联合创始人和董事总经理。Lamb先生是FloSonics Medical和探针开发和商业化中心的董事会成员。Lamb先生拥有McMaster University健康科学系分子神经生物学硕士学位，还拥有Queen&8217；s University工商管理硕士学位。
Damian Lamb has served as our chairman and a member of our board of directors since February 2017. Mr. Lamb is a co-founder of and has been a Managing Director of Genesys Capital Management Inc., a venture capital firm, since 2000. Mr. Lamb is a member of the board of directors of Flosonics Medical and the Centre for Probe Development and Commercialization. Mr. Lamb holds an MS in Molecular Neurobiology from McMaster University, Faculty of Health Sciences and also holds an MBA from Queen’s University. - Damian Lamb自2017年2月以来一直担任我们的董事长兼董事会成员。Lamb自2000年起担任Genesys Capital Management Inc.（一家风险投资公司）联合创始人和董事总经理。Lamb先生是FloSonics Medical和探针开发和商业化中心的董事会成员。Lamb先生拥有McMaster University健康科学系分子神经生物学硕士学位，还拥有Queen&8217；s University工商管理硕士学位。
- Damian Lamb has served as our chairman and a member of our board of directors since February 2017. Mr. Lamb is a co-founder of and has been a Managing Director of Genesys Capital Management Inc., a venture capital firm, since 2000. Mr. Lamb is a member of the board of directors of Flosonics Medical and the Centre for Probe Development and Commercialization. Mr. Lamb holds an MS in Molecular Neurobiology from McMaster University, Faculty of Health Sciences and also holds an MBA from Queen’s University.
- Pablo Cagnoni
-
暂无中文简介
Pablo Cagnoni has served as a member of our board of directors since December 2019. Since June 2018 Dr. Cagnoni has served as the Chief Executive Officer and a member of the board of directors of Rubius Therapeutics, Inc., a biotechnology company. From 2015 until 2018 Dr. Cagnoni served as President and Chief Executive Officer of Tizona Therapeutics, Inc., an oncology company. Dr. Cagnoni previously served as Managing Director of MPM Capital, a healthcare investment firm, from May 2015 until 2016 and as President of Onyx Pharmaceuticals, Inc., a biopharmaceutical company, from 2013 to 2015. Dr. Cagnoni received an MD from the University of Buenos Aires School of Medicine and completed post-doctoral work in Hematology and Oncology at the Mount Sinai Medical Center in New York and in Stem Cell Transplantation at the University of Colorado Health Sciences Center. -
暂无中文简介
- Pablo Cagnoni has served as a member of our board of directors since December 2019. Since June 2018 Dr. Cagnoni has served as the Chief Executive Officer and a member of the board of directors of Rubius Therapeutics, Inc., a biotechnology company. From 2015 until 2018 Dr. Cagnoni served as President and Chief Executive Officer of Tizona Therapeutics, Inc., an oncology company. Dr. Cagnoni previously served as Managing Director of MPM Capital, a healthcare investment firm, from May 2015 until 2016 and as President of Onyx Pharmaceuticals, Inc., a biopharmaceutical company, from 2013 to 2015. Dr. Cagnoni received an MD from the University of Buenos Aires School of Medicine and completed post-doctoral work in Hematology and Oncology at the Mount Sinai Medical Center in New York and in Stem Cell Transplantation at the University of Colorado Health Sciences Center.
- Pablo Cagnoni
-
Pablo Cagnoni是我们的董事会成员。Cagnoni博士在过去的二十年中赢得了工业肿瘤临床开发和公司建设领导者的声誉。他在20多种改变生命的治疗方法的开发，批准和商业化中发挥了关键作用，包括Afinitor，Kyprolis和Tarceva。卡格诺尼目前担任Rubius Therapeutics的总裁兼首席执行官。此前，他曾担任Tizona Therapeutics的总裁兼首席执行官，Tizona Therapeutics是一家私营生物技术公司，致力于开发用于治疗癌症的下一代免疫疗法。卡格诺尼博士作为蒂索纳公司的第一名员工加入了该公司，并发展了该组织，以支持其首次研究性新药申请的提交。任职Tizona公司之前，他曾担任Onyx Pharmaceuticals公司（被Amgen公司收购）的总裁，在那里他曾担任全球战略监督和业务问责制（从早期产品开发到Onyx投资组合商业化）。他于2013年3月加入Onyx公司，担任执行副总裁，负责全球研究与开发和技术运营，并于2013年10月Onyx公司成为Amgen公司的子公司时被任命为总裁。此前，Cagnoni博士是Novartis Oncology的高级副总裁兼临床开发全球主管。在其职业生涯的早期，卡格诺尼博士曾担任科罗拉多大学骨髓移植计划的医学助理教授，在那里他曾照顾接受干细胞移植的患者。卡格诺尼博士获得了布宜诺斯艾利斯大学医学院的医学学位，并在纽约西奈山医学中心完成了血液学和肿瘤学研究金，并在科罗拉多大学健康科学中心完成了干细胞移植研究金。Cagnoni博士是Fusion Pharmaceuticals，Repertoire Immune Medicines，Synthekine和Tizona Therapeutics的董事会成员。
Pablo Cagnoni is a member of our board of directors. Dr. Cagnoni has spent the last two decades earning a reputation as a leader in industrial oncology clinical development and company building. He has played a key role in the development, approval and commercialization of more than 20 life-changing treatments, including Afinitor, Kyprolis and Tarceva.Dr. Cagnoni currently serves as President and CEO of Rubius Therapeutics. Previously, he served as President and Chief Executive Officer of Tizona Therapeutics, a privately held biotech company focused on developing next generation immunotherapies for the treatment of cancer. Dr. Cagnoni joined Tizona as the company’s first employee and grew the organization to support the filing of its first Investigational New Drug application. Prior to Tizona, he served as President of Onyx Pharmaceuticals acquired by Amgen, where Dr. Cagnoni had global strategic oversight and accountability of the business from early product development to commercialization of the Onyx portfolio. He joined Onyx in March 2013 as Executive Vice President, Global Research and Development and Technical Operations, and was named President in October 2013 when Onyx became an Amgen subsidiary. Previously, Dr. Cagnoni was Senior Vice President and Global Head of Clinical Development at Novartis Oncology. Earlier in his career, Dr. Cagnoni served as Assistant Professor of Medicine, University of Colorado Bone Marrow Transplant Program, where he cared for patients undergoing stem cell transplants. Dr. Cagnoni earned his medical degree from University Buenos Aires School of Medicine, and he completed his fellowship in Hematology and Oncology at the Mount Sinai Medical Center, New York and a fellowship in Stem Cell Transplantation at the University of Colorado Health Sciences Center. Dr. Cagnoni is a member of the Board of Directors for Fusion Pharmaceuticals, Repertoire Immune Medicines, Synthekine and Tizona Therapeutics. - Pablo Cagnoni是我们的董事会成员。Cagnoni博士在过去的二十年中赢得了工业肿瘤临床开发和公司建设领导者的声誉。他在20多种改变生命的治疗方法的开发，批准和商业化中发挥了关键作用，包括Afinitor，Kyprolis和Tarceva。卡格诺尼目前担任Rubius Therapeutics的总裁兼首席执行官。此前，他曾担任Tizona Therapeutics的总裁兼首席执行官，Tizona Therapeutics是一家私营生物技术公司，致力于开发用于治疗癌症的下一代免疫疗法。卡格诺尼博士作为蒂索纳公司的第一名员工加入了该公司，并发展了该组织，以支持其首次研究性新药申请的提交。任职Tizona公司之前，他曾担任Onyx Pharmaceuticals公司（被Amgen公司收购）的总裁，在那里他曾担任全球战略监督和业务问责制（从早期产品开发到Onyx投资组合商业化）。他于2013年3月加入Onyx公司，担任执行副总裁，负责全球研究与开发和技术运营，并于2013年10月Onyx公司成为Amgen公司的子公司时被任命为总裁。此前，Cagnoni博士是Novartis Oncology的高级副总裁兼临床开发全球主管。在其职业生涯的早期，卡格诺尼博士曾担任科罗拉多大学骨髓移植计划的医学助理教授，在那里他曾照顾接受干细胞移植的患者。卡格诺尼博士获得了布宜诺斯艾利斯大学医学院的医学学位，并在纽约西奈山医学中心完成了血液学和肿瘤学研究金，并在科罗拉多大学健康科学中心完成了干细胞移植研究金。Cagnoni博士是Fusion Pharmaceuticals，Repertoire Immune Medicines，Synthekine和Tizona Therapeutics的董事会成员。
- Pablo Cagnoni is a member of our board of directors. Dr. Cagnoni has spent the last two decades earning a reputation as a leader in industrial oncology clinical development and company building. He has played a key role in the development, approval and commercialization of more than 20 life-changing treatments, including Afinitor, Kyprolis and Tarceva.Dr. Cagnoni currently serves as President and CEO of Rubius Therapeutics. Previously, he served as President and Chief Executive Officer of Tizona Therapeutics, a privately held biotech company focused on developing next generation immunotherapies for the treatment of cancer. Dr. Cagnoni joined Tizona as the company’s first employee and grew the organization to support the filing of its first Investigational New Drug application. Prior to Tizona, he served as President of Onyx Pharmaceuticals acquired by Amgen, where Dr. Cagnoni had global strategic oversight and accountability of the business from early product development to commercialization of the Onyx portfolio. He joined Onyx in March 2013 as Executive Vice President, Global Research and Development and Technical Operations, and was named President in October 2013 when Onyx became an Amgen subsidiary. Previously, Dr. Cagnoni was Senior Vice President and Global Head of Clinical Development at Novartis Oncology. Earlier in his career, Dr. Cagnoni served as Assistant Professor of Medicine, University of Colorado Bone Marrow Transplant Program, where he cared for patients undergoing stem cell transplants. Dr. Cagnoni earned his medical degree from University Buenos Aires School of Medicine, and he completed his fellowship in Hematology and Oncology at the Mount Sinai Medical Center, New York and a fellowship in Stem Cell Transplantation at the University of Colorado Health Sciences Center. Dr. Cagnoni is a member of the Board of Directors for Fusion Pharmaceuticals, Repertoire Immune Medicines, Synthekine and Tizona Therapeutics.
- Steve Gannon
-
Steve Gannon于2014年6月成为董事会成员。他是Aptalis Pharma Inc.的一位高级副总裁兼首席财务总监及财务主管，直到2014年2月它被卖给了Forest Laboratories。2006年加入Aptalis Pharma之前，1999年至2006年Gannon先生担任Cryocath Technologies Inc.的首席财务官；1996年至1999年，担任 Astrazeneca Canada Inc.研究部的财务和行政总监；1989年至1995年，在Mallinckrodt Medical Inc.加拿大的业务担任首席财务官。他于1983年获得加拿大蒙特利尔 Concordia University的会计和业务系统的商学士学位，1995年完成了加拿大安大略省业务Richard Ivey School of Business at the University of Western Ontario的执行课程。自1985年以来，他一直是一名注册会计师。
Steve Gannon has served as a member of our board of directors since January 2020. Mr. Gannon has served on the board of directors of Xenon Pharmaceutics Inc., a biotechnology company, since May 2015 and the board of directors of enGene Inc., a biotechnology company, since February 2017. From June 2014 to March 2018 Mr. Gannon served on the board of directors of Advanced Accelerator Applications SA, a healthcare company acquired by Novartis in January 2018. Mr. Gannon was Chief Financial Officer, Senior Vice President of Finance and Treasurer at Aptalis Pharma Inc. until February 2014 after which it was sold to Forest Laboratories. Prior to joining Aptalis in 2006 Mr. Gannon served as the Chief Financial Officer for Cryocath Technologies Inc. from 1999 to 2006 as the Director of Finance and Administration of the Research Division of AstraZeneca Canada Inc. from 1996 to 1999 and as the Chief Financial Officer of Mallinckrodt Medical Inc.’s Canadian operations from 1989 to 1995. He received a BComm in Accounting and Business Systems from Concordia University in Montreal, Canada in 1983 and completed the Executive Program at the Richard Ivey School of Business at the University of Western Ontario in Ontario, Canada in 1995. He has been a Chartered Accountant since 1985. - Steve Gannon于2014年6月成为董事会成员。他是Aptalis Pharma Inc.的一位高级副总裁兼首席财务总监及财务主管，直到2014年2月它被卖给了Forest Laboratories。2006年加入Aptalis Pharma之前，1999年至2006年Gannon先生担任Cryocath Technologies Inc.的首席财务官；1996年至1999年，担任 Astrazeneca Canada Inc.研究部的财务和行政总监；1989年至1995年，在Mallinckrodt Medical Inc.加拿大的业务担任首席财务官。他于1983年获得加拿大蒙特利尔 Concordia University的会计和业务系统的商学士学位，1995年完成了加拿大安大略省业务Richard Ivey School of Business at the University of Western Ontario的执行课程。自1985年以来，他一直是一名注册会计师。
- Steve Gannon has served as a member of our board of directors since January 2020. Mr. Gannon has served on the board of directors of Xenon Pharmaceutics Inc., a biotechnology company, since May 2015 and the board of directors of enGene Inc., a biotechnology company, since February 2017. From June 2014 to March 2018 Mr. Gannon served on the board of directors of Advanced Accelerator Applications SA, a healthcare company acquired by Novartis in January 2018. Mr. Gannon was Chief Financial Officer, Senior Vice President of Finance and Treasurer at Aptalis Pharma Inc. until February 2014 after which it was sold to Forest Laboratories. Prior to joining Aptalis in 2006 Mr. Gannon served as the Chief Financial Officer for Cryocath Technologies Inc. from 1999 to 2006 as the Director of Finance and Administration of the Research Division of AstraZeneca Canada Inc. from 1996 to 1999 and as the Chief Financial Officer of Mallinckrodt Medical Inc.’s Canadian operations from 1989 to 1995. He received a BComm in Accounting and Business Systems from Concordia University in Montreal, Canada in 1983 and completed the Executive Program at the Richard Ivey School of Business at the University of Western Ontario in Ontario, Canada in 1995. He has been a Chartered Accountant since 1985.
- Heather Preston
-
Heather Preston博士自2007年12月就是董事会成员。自2005年，Preston博士在TPG生物科技担任常务董事，该公司是一家生物科技风险投资公司。在加入TPG生物科技之前，Preston博士在摩根大通公司合作伙伴-LLC做了两年的医疗设备与生物科技风险投资的投资人，LLC是一家私人直接投资公司。在那之前，她是风险投资公司恩颐投资的入驻企业家。从1997年到2002年，Preston博士在位于纽约的麦肯锡担任药品和医疗产品咨询的负责人。Preston博士目前是许多私企董事会的常任董事。Preston博士取得了牛津大学医学博士学位以及伦敦大学生物化学理学士学位。
Heather Preston has served on our board of directors since February 2020. Dr. Preston is currently managing partner at Pivotal bioVentures, a venture capital firm, which she joined in July 2018. From May 2005 to July 2018 Dr. Preston was a firm partner and managing director of TPG Biotech, a venture capital firm. She currently serves on the boards of directors of Karuna Therapeutics since March 2019 Oxford Biomedica since March 2019 and Entasis Therapeutics Inc. since August 2017 and on the boards of a number of private companies. Dr. Preston previously served on the board of directors of Albireo Pharma, Inc. from November 2016 to June 2018 Alder Biopharmaceuticals from December 2007 to October 2019 and Otonomy, Inc. from August 2010 until February 2020. Prior to joining TPG Biotech, Dr. Preston served for two years as a medical device and biotechnology venture capital investor at JP Morgan Partners, LLC, a private equity firm. Prior to that, she was an entrepreneur-in-residence at New Enterprise Associates, a venture capital firm. Dr. Preston holds a B.Sc.Hons degree in biochemistry from the University of London and an M.B.B.Chir degree in medicine from the University of Oxford. After leaving Oxford, Dr. Preston completed a postdoctoral fellowship in molecular biology at the Dana Farber Cancer Institute, Harvard University. Dr. Preston completed her training in Internal Medicine at the Massachusetts General Hospital and then sub-specialized in Gastroenterology and Hepatology at U.C.S.F. During Dr. Preston's academic career, she was the recipient of a Fulbright Scholarship, a Fulbright Cancer Research Scholarship, a Harlech Scholarship, and a Science and Engineering Research Council Post-Doctoral Fellowship Award. - Heather Preston博士自2007年12月就是董事会成员。自2005年，Preston博士在TPG生物科技担任常务董事，该公司是一家生物科技风险投资公司。在加入TPG生物科技之前，Preston博士在摩根大通公司合作伙伴-LLC做了两年的医疗设备与生物科技风险投资的投资人，LLC是一家私人直接投资公司。在那之前，她是风险投资公司恩颐投资的入驻企业家。从1997年到2002年，Preston博士在位于纽约的麦肯锡担任药品和医疗产品咨询的负责人。Preston博士目前是许多私企董事会的常任董事。Preston博士取得了牛津大学医学博士学位以及伦敦大学生物化学理学士学位。
- Heather Preston has served on our board of directors since February 2020. Dr. Preston is currently managing partner at Pivotal bioVentures, a venture capital firm, which she joined in July 2018. From May 2005 to July 2018 Dr. Preston was a firm partner and managing director of TPG Biotech, a venture capital firm. She currently serves on the boards of directors of Karuna Therapeutics since March 2019 Oxford Biomedica since March 2019 and Entasis Therapeutics Inc. since August 2017 and on the boards of a number of private companies. Dr. Preston previously served on the board of directors of Albireo Pharma, Inc. from November 2016 to June 2018 Alder Biopharmaceuticals from December 2007 to October 2019 and Otonomy, Inc. from August 2010 until February 2020. Prior to joining TPG Biotech, Dr. Preston served for two years as a medical device and biotechnology venture capital investor at JP Morgan Partners, LLC, a private equity firm. Prior to that, she was an entrepreneur-in-residence at New Enterprise Associates, a venture capital firm. Dr. Preston holds a B.Sc.Hons degree in biochemistry from the University of London and an M.B.B.Chir degree in medicine from the University of Oxford. After leaving Oxford, Dr. Preston completed a postdoctoral fellowship in molecular biology at the Dana Farber Cancer Institute, Harvard University. Dr. Preston completed her training in Internal Medicine at the Massachusetts General Hospital and then sub-specialized in Gastroenterology and Hepatology at U.C.S.F. During Dr. Preston's academic career, she was the recipient of a Fulbright Scholarship, a Fulbright Cancer Research Scholarship, a Harlech Scholarship, and a Science and Engineering Research Council Post-Doctoral Fellowship Award.
- Elisha P. Gould III
-
Elisha P. Gould III ，他担任我们董事会的董事（自2006年8月以来）。自1994年以来，他在 Adams Street Partners, LLC（一个私募股权公司）和其前任机构任职。他现在是合伙人和直接投资的负责人。他持有达特茅斯学院（Dartmouth College）的学士学位和斯坦福大学商学院 （ Stanford Graduate School of Business ）的工商管理硕士学位。
Elisha P. Gould III has served as a member of our board of directors since September 2017. Mr. Gould is currently a Partner and Head of Venture/Growth Equity Investments at Adams Street Partners, LLC, a global private equity firm, and has been employed by Adams Street Partners or its predecessor organizations since 1994. Since 2014 Mr. Gould currently serves on the board of directors of Aptinyx Inc., a biopharmaceutical company focused on the development of product candidates for the treatment of brain and nervous system disorders. Mr. Gould has served on the board of directors of Corvus Pharmaceuticals, Inc. and, from 2006 to 2017 he served on the board of directors of OncoMed Pharmaceuticals, Inc. Mr. Gould received an AB in Engineering Science from Dartmouth College and an MBA from the Stanford University Graduate School of Business. Mr. Gould will resign immediately prior to the effectiveness of the registration statement of which this prospectus forms as part. - Elisha P. Gould III ，他担任我们董事会的董事（自2006年8月以来）。自1994年以来，他在 Adams Street Partners, LLC（一个私募股权公司）和其前任机构任职。他现在是合伙人和直接投资的负责人。他持有达特茅斯学院（Dartmouth College）的学士学位和斯坦福大学商学院 （ Stanford Graduate School of Business ）的工商管理硕士学位。
- Elisha P. Gould III has served as a member of our board of directors since September 2017. Mr. Gould is currently a Partner and Head of Venture/Growth Equity Investments at Adams Street Partners, LLC, a global private equity firm, and has been employed by Adams Street Partners or its predecessor organizations since 1994. Since 2014 Mr. Gould currently serves on the board of directors of Aptinyx Inc., a biopharmaceutical company focused on the development of product candidates for the treatment of brain and nervous system disorders. Mr. Gould has served on the board of directors of Corvus Pharmaceuticals, Inc. and, from 2006 to 2017 he served on the board of directors of OncoMed Pharmaceuticals, Inc. Mr. Gould received an AB in Engineering Science from Dartmouth College and an MBA from the Stanford University Graduate School of Business. Mr. Gould will resign immediately prior to the effectiveness of the registration statement of which this prospectus forms as part.
高管简历
中英对照 | 中文 | 英文- John Crowley
John Crowley自2019年2月起担任我们的首席财务官。2016年11月至2019年1月，克劳利先生担任临床阶段免疫肿瘤公司Merus，Inc.的执行Vice President和首席财务官。2013年9月至2016年11月，克劳利先生担任合同研究机构Charles River Laboratories，Inc.的公司高级副总裁，公司财务总监兼首席会计官。Crowley先生是一名注册会计师，并在巴布森学院（Babson College）获得经济学和会计学学士学位。
John Crowley has served as our Chief Financial Officer since February 2019. From November 2016 to January 2019 Mr. Crowley served as Executive Vice President and Chief Financial Officer at Merus, Inc., a clinical-stage immuno-oncology company. From September 2013 to November 2016 Mr. Crowley served as the Corporate Senior Vice President, Corporate Controller and Chief Accounting Officer at Charles River Laboratories, Inc., a contract research organization. Mr. Crowley is a Certified Public Accountant and received a BS from Babson College in both Economics and Accountancy.- John Crowley自2019年2月起担任我们的首席财务官。2016年11月至2019年1月，克劳利先生担任临床阶段免疫肿瘤公司Merus，Inc.的执行Vice President和首席财务官。2013年9月至2016年11月，克劳利先生担任合同研究机构Charles River Laboratories，Inc.的公司高级副总裁，公司财务总监兼首席会计官。Crowley先生是一名注册会计师，并在巴布森学院（Babson College）获得经济学和会计学学士学位。
- John Crowley has served as our Chief Financial Officer since February 2019. From November 2016 to January 2019 Mr. Crowley served as Executive Vice President and Chief Financial Officer at Merus, Inc., a clinical-stage immuno-oncology company. From September 2013 to November 2016 Mr. Crowley served as the Corporate Senior Vice President, Corporate Controller and Chief Accounting Officer at Charles River Laboratories, Inc., a contract research organization. Mr. Crowley is a Certified Public Accountant and received a BS from Babson College in both Economics and Accountancy.
- John Valliant
John Valliant是我们的创始人，自2014年12月起担任首席执行官和董事会成员。从2008年3月到2018年10月，Valliant博士担任Probe开发和商业化中心（CPDC）的首席执行官，这是一家放射性药物研究与开发中心，他也创立了该中心。Valliant博士从1999年开始还担任麦克马斯特大学（McMaster University）化学与化学生物系的教授。Valliant博士在麦克马斯特大学（McMaster University）完成博士学位，还在哈佛医学院（Harvard Medical School）的阿伦·琼斯（Alun G.Jones）教授和麻省理工学院（Massachusetts Institute of Technology）的艾伦·戴维森（Alan Davison）教授的共同监督下完成博士后奖学金。
John Valliant is our founder and has served as Chief Executive Officer and as a member of our board of directors since December 2014. From March 2008 to October 2018 Dr. Valliant was the Chief Executive Officer at the Centre for Probe Development and Commercialization, or CPDC, a radiopharmaceutical research and development center, which he also founded. Since 1999 Dr. Valliant has also served as a Professor in the Department of Chemistry and Chemical Biology at McMaster University. Dr. Valliant completed his PhD at McMaster University, and also completed a post-doctoral fellowship under the joint supervision of professors Alun G. Jones of Harvard Medical School and Alan Davison of the Massachusetts Institute of Technology.- John Valliant是我们的创始人，自2014年12月起担任首席执行官和董事会成员。从2008年3月到2018年10月，Valliant博士担任Probe开发和商业化中心（CPDC）的首席执行官，这是一家放射性药物研究与开发中心，他也创立了该中心。Valliant博士从1999年开始还担任麦克马斯特大学（McMaster University）化学与化学生物系的教授。Valliant博士在麦克马斯特大学（McMaster University）完成博士学位，还在哈佛医学院（Harvard Medical School）的阿伦·琼斯（Alun G.Jones）教授和麻省理工学院（Massachusetts Institute of Technology）的艾伦·戴维森（Alan Davison）教授的共同监督下完成博士后奖学金。
- John Valliant is our founder and has served as Chief Executive Officer and as a member of our board of directors since December 2014. From March 2008 to October 2018 Dr. Valliant was the Chief Executive Officer at the Centre for Probe Development and Commercialization, or CPDC, a radiopharmaceutical research and development center, which he also founded. Since 1999 Dr. Valliant has also served as a Professor in the Department of Chemistry and Chemical Biology at McMaster University. Dr. Valliant completed his PhD at McMaster University, and also completed a post-doctoral fellowship under the joint supervision of professors Alun G. Jones of Harvard Medical School and Alan Davison of the Massachusetts Institute of Technology.
- Eric Burak
Eric Burak自2017年2月起担任我们的首席科学官。2012年10月至2017年2月，Burak博士担任CPDC的首席科学官。在此之前，2011年6月至2012年10月，Burak博士担任Theracos，Inc.（一家制药研究与开发公司）的开发Vice President。Burak博士拥有坦普尔大学（Temple University）分析化学博士学位和德雷克塞尔大学（Drexel University）化学学士学位。
Eric Burak has served as our Chief Scientific Officer since February 2017. From October 2012 to February 2017 Dr. Burak served as the Chief Scientific Officer at CPDC. Prior to that, from June 2011 to October 2012 Dr. Burak served as Vice President, Development at Theracos, Inc., a pharmaceutical research and development company. Dr. Burak holds a PhD in Analytical Chemistry from Temple University and a BS in Chemistry from Drexel University.- Eric Burak自2017年2月起担任我们的首席科学官。2012年10月至2017年2月，Burak博士担任CPDC的首席科学官。在此之前，2011年6月至2012年10月，Burak博士担任Theracos，Inc.（一家制药研究与开发公司）的开发Vice President。Burak博士拥有坦普尔大学（Temple University）分析化学博士学位和德雷克塞尔大学（Drexel University）化学学士学位。
- Eric Burak has served as our Chief Scientific Officer since February 2017. From October 2012 to February 2017 Dr. Burak served as the Chief Scientific Officer at CPDC. Prior to that, from June 2011 to October 2012 Dr. Burak served as Vice President, Development at Theracos, Inc., a pharmaceutical research and development company. Dr. Burak holds a PhD in Analytical Chemistry from Temple University and a BS in Chemistry from Drexel University.
- James O'Leary
James O’Leary自2020年3月起担任首席医疗官。从2019年11月至2020年3月，O’Leary博士担任我们的临时首席医疗官。在此之前，O’Leary博士于2018年10月至2020年3月担任多家生物技术公司的独立顾问，于2017年5月至2018年9月担任全球制药公司武田制药有限公司的Vice President/全球项目负责人，并于2015年11月至2017年5月担任独立顾问。在此之前，从2008年11月至2014年10月，O’Leary博士担任ImmunoGen，Inc.公司的Vice President兼首席医疗官，该公司是一家生物技术公司，专注于开发抗体-药物结合技术来治疗癌症。O’Leary博士在布鲁克林的纽约州立大学健康科学中心（SUNY Health Science Center）获得医学博士学位，在霍夫斯特拉大学（Hofstra University）获得学士学位。
James O'Leary has served as Chief Medical Officer since March 2020. From November 2019 to March 2020 Dr. O'Leary served as Fusion Pharmaceuticals Inc. Interim Chief Medical Officer. Prior to this role, Dr. O'Leary was an independent consultant to several biotech companies from October 2018 to March 2020 Vice President/Global Project Leader at Takeda Pharmaceuticals Company Limited, a global pharmaceutical company, from May 2017 to September 2018 and an independent consultant from November 2015 to May 2017. Prior to that, from November 2008 to October 2014 Dr. O'Leary was the Vice President and Chief Medical Officer of ImmunoGen, Inc., a biotechnology company focused on the development of antibody-drug conjugate technology to treat cancer. Dr. O'Leary received his MD from SUNY Health Science Center at Brooklyn and received his BS from Hofstra University.- James O’Leary自2020年3月起担任首席医疗官。从2019年11月至2020年3月，O’Leary博士担任我们的临时首席医疗官。在此之前，O’Leary博士于2018年10月至2020年3月担任多家生物技术公司的独立顾问，于2017年5月至2018年9月担任全球制药公司武田制药有限公司的Vice President/全球项目负责人，并于2015年11月至2017年5月担任独立顾问。在此之前，从2008年11月至2014年10月，O’Leary博士担任ImmunoGen，Inc.公司的Vice President兼首席医疗官，该公司是一家生物技术公司，专注于开发抗体-药物结合技术来治疗癌症。O’Leary博士在布鲁克林的纽约州立大学健康科学中心（SUNY Health Science Center）获得医学博士学位，在霍夫斯特拉大学（Hofstra University）获得学士学位。
- James O'Leary has served as Chief Medical Officer since March 2020. From November 2019 to March 2020 Dr. O'Leary served as Fusion Pharmaceuticals Inc. Interim Chief Medical Officer. Prior to this role, Dr. O'Leary was an independent consultant to several biotech companies from October 2018 to March 2020 Vice President/Global Project Leader at Takeda Pharmaceuticals Company Limited, a global pharmaceutical company, from May 2017 to September 2018 and an independent consultant from November 2015 to May 2017. Prior to that, from November 2008 to October 2014 Dr. O'Leary was the Vice President and Chief Medical Officer of ImmunoGen, Inc., a biotechnology company focused on the development of antibody-drug conjugate technology to treat cancer. Dr. O'Leary received his MD from SUNY Health Science Center at Brooklyn and received his BS from Hofstra University.